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The Negative Outcomes of a Positive Result
New genetic tests may provide more stress than information for patients
by Maggie Masterson
The rise of  genetic testing has led to thousands of  women undergoing BRCA testing in the past 
15 years, but novel gene mutations are leading to a more expansive and more controversial test. 
BRCA is a gene that protects us from developing tumors, so a mutation on BRCA implicates a 
high risk of  cancer, but it is not the only gene linked to hereditary cancers. Women are now opting to undergo 
panel testing, which involves not only testing for a mutation on the well-known and extensively understood 
BRCA gene, but also on newly discovered 
genes, about which geneticists are still at a 
knowledge deficit, as reported in Reuters.
A mutation in either the BRCA 1 or BRCA 2 
gene will greatly increase a person’s lifetime 
risk of  breast and ovarian cancer. The 
lifetime risk of  developing breast cancer for 
someone with a BRCA mutation is up to 87 
percent, and up to 44 percent for ovarian 
cancer. Women are the highest risk group for 
these cancers, since they have more breast 
tissue than men, and because only females 
possess ovaries. For this reason, it is mainly 
women who opt for BRCA testing, although 
men can also be screened to assess their 
status as a carrier of  the gene. However, 
there are women developing hereditary breast cancers who test negative for a BRCA mutation, indicating that 
there are other genes linked to these hereditary cancers. This is where genetic panel testing comes into play.
A genetic panel test differs from a normal genetic test in that it will screen many genes rather than just targeting 
one. For example, an Ambry Genetics BreastNext panel test will screen for a mutation in BRCA 1 or 2, as well 
as on fifteen other genes linked to breast cancer, such as PALB2 and TP53. A test that provides more genetic 
information should lead to better medical management and risk assessment, right? Well, the catch with these 
novel genes is that their expression and relative risk to certain cancers are mostly unknown. A woman who 
would have previously breathed a sigh of  relief  over a negative BRCA result may now be burdened with the 
information that she has a mutation on a gene such as TP53. Genetic counselors cannot articulate the exact 
risks that accompany such mutations and, more alarmingly, cannot confidently say that a mutation in one of  
these genes is malignant. The genes in question are so new to us that testing for them may cause more harm 
than good. 
We are continually gathering more information about these new genes, which is one benefit of  these controversial 
panel tests: they are slowly helping geneticists learn more about these novel genes. But for now many geneticists 
are calling for a moratorium on these tests, until more clinically relevant information is available. As time passes, 
it will become more clear if  genetic paneling is helping or hurting patients.
“The catch with these novel genes is that their expression and 
relative risk to certain cancers are mostly unknown.”
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